NCT03686488 2026-03-02
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
National Cancer Center Hospital East
Providence Health & Services
Merck Sharp & Dohme LLC
UCB Pharma